| Identification | Back Directory | [Name]
[1,2,4]Triazolo[1,5-a]pyrimidine-4(7H)-acetamide, N-[2-chloro-4-(trifluoromethyl)phenyl]-2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-[4-[(3-hydroxy-2-pyridinyl)carbonyl]-1-piperazinyl]-7-oxo- | [CAS]
2869954-98-1 | [Synonyms]
Werner syndrome RecQ helicase-IN-3
N-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-(4-(3-hydroxypicolinoyl)piperazin-1-yl)-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidin-4(7H)-yl)acetamide
[1,2,4]Triazolo[1,5-a]pyrimidine-4(7H)-acetamide, N-[2-chloro-4-(trifluoromethyl)phenyl]-2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-[4-[(3-hydroxy-2-pyridinyl)carbonyl]-1-piperazinyl]-7-oxo- | [Molecular Formula]
C31H30ClF3N8O5 | [MOL File]
2869954-98-1.mol | [Molecular Weight]
687.07 |
| Hazard Information | Back Directory | [Uses]
Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 μM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity[1]. | [in vivo]
Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse[1]. | Animal Model: | Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells)[1] | | Dosage: | 120 mg/kg | | Administration: | P.o.; daily for 22 days | | Result: | Inhibited tumor growth. |
| [References]
[1] Vincent Bordas, et al. Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn). WO2022249060A1. |
|
|